“As we look at our opportunities for GARDASIL, we do expect growth in 2025 and beyond, but that does not contemplate any change in the dosing schedule for the United States.”

In context

“cervical cancer in females. They have a very high statistical bar in the long term. They want very long-term durability of protection. In terms of the ACIP, there's no agenda posted for the August, September and October. However, this was sort of a topic that got postponed. So we imagine that there will be discussion about it. But we are very clear on the safety and efficacy and the clear disparity between the FDA's high evidentiary standard and any data to date in relationship to a single dose. Caroline A. Litchfield: And then in terms of the commercial, in the United States, we saw strong growth driven by price and demand, but that was mostly offset by the CDC channel, where there was a buydown in the second quarter this year greater than what we had seen in the second quarter of 2024. As we look at our opportunities for GARDASIL, we do expect growth in 2025 and beyond, but that does not contemplate any change in the dosing schedule for the United States. And we'll need to see what happens as the ACIP continue those discussions. As it pertains to China, as noted in the prepared remarks, demand remains soft and inventory remains elevated. We are on the ground doing all we can to activate demand, both with females as well as now with males. That said, we will not ship further product this year, and we will assess at the year-end on what the appropriate schedule should be for 2026. I should note, GARDASIL China represents a fraction of our company now, much less than 1%. We're not counting on it for growth. We are counting on our new products, the excellent execution we have in our existing products to drive growth for our company in the second half of this year and into the future. Operator: Our next question comes from Evan Seigerman with B”